Hosted on MSN15d
EU medicines agency quits X, moves to Bluesky
AMSTERDAM (Reuters) - The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media ...
Fact Check: Moderna began clinical trials of COVID vaccine in 2020, not 2017
Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
Pharmabiz20h
Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema
Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...
Euro Weekly News1d
Flu season crisis: Polands seeks European aid
Flu season has hit Poland hard, straining the country’s healthcare system. In response, Health Minister Izabela Leszczyna has ...
Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2506, a Proposed Biosimilar to Simponi®, in the European Union
Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...
LAFFAZ10d
European Medicines Agency quits X amid content moderation concerns, joins Bluesky
The European Medicines Agency (EMA) announced on Monday that it will be discontinuing its presence on X, opting instead to utilize rival platform Bluesky.
ophthalmologytimes8d
CHMP of the European Medicines Agency issues positive opinion on 2 aflibercept biosimilars
The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...